1-3 of 3
Mark J Rose
Close
Sort by
Journal Articles

Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma

Carole Soussain, Samar Issa, Katharine L Lewis, Christian Grommes, Judith Fox, Renee Ward, Caryn Peterson, Matt Cravets, Anita Mathias, Judith Sosa, Brian J Kirby, Zhaoqing Ding, Isharat Yusuf, Mark J Rose, Marcos W Steinberg, Han W. Tun
Journal: Blood
Blood (2022) 140 (Supplement 1): 12068–12069.
https://doi.org/10.1182/blood-2022-158599
Published: 2022
Journal Articles

Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GB5121, a CNS-Penetrant BTK Inhibitor, in Healthy Subjects

Brian J Kirby, Richard Aranda, Renee Ward, Marcos W Steinberg, Maria Hernandez, Judith Sosa, Matt Cravets, Mark J Rose, Robin Osterhout, Zhaoqing Ding, Isharat Yusuf, Judith Fox, Anita Mathias
Journal: Blood
Blood (2022) 140 (Supplement 1): 11570–11571.
https://doi.org/10.1182/blood-2022-160388
Published: 2022
Journal Articles

GB5121, a Brain-Penetrant, Irreversible BTK Inhibitor, Demonstrates Potent Anti-Tumor Activity in a Novel Mouse Model of Intracranial Lymphoma

Isharat Yusuf, Marcos W Steinberg, Maricel Gozo, Bryan Clemons, Kay Hou, David Guimond, Mark J Rose, Kristen Taylor Meadows, Laura Carter
Journal: Blood
Blood (2022) 140 (Supplement 1): 8878–8879.
https://doi.org/10.1182/blood-2022-159088
Published: 2022